S1802 Standard Systemic Therapy with or without Definitive Treatment in Treating Participants with Metastatic Prostate Cancer - Mercy Medical Center

S1802 Standard Systemic Therapy with or without Definitive Treatment in Treating Participants with Metastatic Prostate Cancer

Posted on: January 30, 2020

This phase III trial studies whether the addition of definitive treatment (radiation or surgical removal) of the primary tumor to standard systemic therapy for patients with prostate cancer, may help prevent the cancer from the spreading to other parts of their body. Removing the prostate by either surgery or radiation therapy in addition to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading. Eligibility includes being at least 18 years old and:

All patients must have a histologically or cytologically proven diagnosis of adenocarcinoma of the prostate.

Patients must have an intact prostate.

Must have metastatic disease

Leave a Reply

Mercy Medical Center | 1320 Mercy Drive NW, Canton, OH 44708 | info@cantonmercy.org
Contact Us | Careers | Privacy Policy | Copyright © 2017 Mercy Medical Center